Long-Term Quality of Life in Patients With Metastatic Melanoma Treated With Checkpoint Inhibitors

Inclusion Criteria: * Be able to speak and read English * Be able to provide informed consent * Have been diagnosed with metastatic melanoma at age 18 years or older * Have been treated with either single agent or combination checkpoint inhibitor * Be at least 12 months since first dose of above named agents * Received no other systemic therapy after initiation of immunotherapy (interval radiation or surgery will be permitted based on review with primary treating medical oncologist) Exclusion Criteria: * Patients with cognitive, visual, or motor impairment such that they cannot complete the survey as assessed by the research or clinical team * Patients who developed a subsequent cancer after starting on checkpoint inhibitor(s), exclusive of non-melanoma superficial skin cancers * Patients with clinical documentation of progressive disease on the most recent assessment in the electronic medical record * Patients with symptomatic progression but continue on immunotherapy * Note: For any patients where the disease status is not clear, we will confirm that the disease is either stable or responsive with their primary treating medical oncologist